Gunilla Høyer-Hansen - Recent Publications

Morten G. Rasch, Ida K. Lund, Martin Illemann, Gunilla Høyer-Hansen, and Henrik Gårdsvoll:
Purification and characterization of recombinant full-length and protease-domain of murine MMP-9 in Drosophila S2 cells.
Protein Expression and Purification. 2010. 72: 87-94.

Olson, F.J., Sørensen T.T., Ryndel, M., Høyer-Hansen, G. and Fagerberg, B.:
The soluble urokinase-type plasminogen activator receptor is associated with cardiovascular disease and risk factors in patients with symptomatic carotid atherosclerosis.
Clin. Biochem. 2010, 43:124-30.

Lomholt, A.F., Høyer-Hansen, G., Nielsen, H.J. and Christensen I.J.
Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Br J Cancer. 2009, 101:992-7.

Henic, E., Noskova, V., Høyer-Hansen, G., Hansson, S. and Casslén, B.:
Estradiol attenuates EGFnduced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells.-i
Int J Gynecol Cancer. 2009, 19:214-22.

Almasi, C.E., Høyer-Hansen, G., Christensen, I.J. and Pappot, H.:
Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
APMIS. 2009, 117: 755-61

Pragner, G. W., Mihaly, J., Brunner, P.M., Koschelnick, Y., Høyer-Hansen, G. and Binder, B.:
Urokinase (uPA) mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein (XIAP).
Blood. 2009, 113: 1383-90.

Lund, I.K., Jögi, A., Rønø, B., Rasch, M.G., Lund, L.R., Almholt, K., Gårdsvoll, H., Behrendt, N., Rømer, J.R.Høyer-Hansen, G.:
Antibody-mediated targeting of the uPA proteolytic function neutralizes fibrinolysis in vivo.
J Biol Chem. 2008, 283: 32506-15.

Rasch, M.G., Pass, J., Illemann, M., Høyer-Hansen, G. and Lund, I.K.:
"Discrimination of different forms of the murine urokinase receptor on the cell surface using monoclonal antibodies."
J. Immunol. Meth. 2008, 339: 55-65.

Christensen, I.J., Pappot, H. and Høyer-Hansen, G.:
"The plasminogen activation system as a source of prognostic markers in cancer."
In The Cancer Degradome: Proteases and Cancer Biology. Eds. Edwards, D., Høyer-Hansen, G., Blasi, F., Sloane, B.F.
Springer. 2008. In press.

Henic, E., Borgfeldt, C., Christensen, I.J., Casslén, B. and Høyer-Hansen, G.:
"Cleaved forms of the urokinase plasminogen activator receptor in plasma enhance discrimination of benign from malignant disease and predict survival in patients with ovarian cancer."
Clin. Cancer Res., 2008, 14: 5785-5793.

Rash, M.G., Lund, I.K., Almasi, C.E. and Høyer-Hansen, G.:
"Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer."
Front Biosci. 2008, 13: 6752-6762.

Madsen, D.H., Engelholm, L.H., Ingvarsen, S., Hillig, T., Wagenaar-Miller, R.A., Kjøller, L., Gårdsvoll, H., Høyer-Hansen, G., Holmbeck, K., Bugge, T.H. and Behrendt, N.:
"Extracellular collagenases and the endocytic receptor, uPARAP/Endo180, cooperate in fibroblast-mediated collagen degradation."
J. Biol. Chem. , 2007, 282: 27037-27045.

Jögi, A., Pass, J., Høyer-Hansen, G., Lund, L.R., Nielsen B.S., Danø, K. and Rømer, J.:
"Systemic administration of anti-uPAR monoclonal antibodies induces hepatic fibrin deposition in tPA-deficient mice."
J Thromb Hæm. 2007, 5:1936-1944.

Pass, J., Jögi, A., Lund,I.K., Rønø, B., Rasch, M.G., Gårdsvoll,H., Lund, L.R., Ploug, M., Rømer, J., Danø, K. and Høyer-Hansen, G.:
"Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptor-mediated uPA activity in vitro and in vivo."
Thromb.Haem. 2007; 97:1013-22.

Høyer-Hansen, G. and Lund I.K.:
"Urokinase receptor variants in tissue and body fluids."
Adv. Clin. Chem. 2007; 44:65-102.

Ostrowski, S.R., Shulman, C.E., Peshu, N., Høyer-Hansen, G., Pedersen, B.K., Marsh, K. and Ullum, H.:
"Elevated plasma urokinase receptor predicts low birth weight in maternal malaria."
Parasite Immunol. 2007, 29: 37-46.

Ostrowski, S.R., Ravn, P., Høyer-Hansen, G., Ullum, H. and Andersen, A.B.:
"Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy."
Scand J Infect Dis. 2006, 38: 1028-32.

Andersen, A.B., Law, I., Ostrowski, S.R., Lebech, A.M., Høyer-Hansen, G, Højgaard, L., Gerstoft, J., Ullum, H. and Kjær, A.:
"Self-reported fatigue common among optimally treated HIV patients: no correlation with cerebral FDG-PET scanning abnormalities." Neuroimmunomodulation. 2006, 13: 69-75.

Ostrowski, S.R., Katzenstein, T.L., Pedersen, M., Høyer-Hansen, G., Gerstoft, J., Pedersen, B.K. and Ullum, H.:
"Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1nfected patients initiating highly active antiretroviral therapy." -i
Scand J Immunol. 2006, 63: 478-86.

Piironen, T., Haese, A., Huland, H., Steuber, T., Christensen, I.J., Brünner, N., Danø, K.Høyer-Hansen, G. and Lilja, H.:
"Enhanced discrimination of benign from malignant prostatic disease by novel selective measurements of cleaved forms of urokinase receptor in serum."
Clin.Chem. 2006. 52: 838-844.

Henic, E., Sixt, M., Hansson, S., Høyer-Hansen, G., Casslén, B.:
"EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator."
Gynecol.Oncol, 2006, 101: 28-39.

Larsen, M.B., Stephens, R.W., Brünner, N., Nielsen, H.J., Engelholm, L.H., Christensen, I.J., Stetler-Stevenson, W.G. and Høyer-Hansen, G.: "Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients."
Scand. J. Immunol., 2005, 61: 449-460.

Ostrowski, S.R., Piironen T, Høyer-Hansen, G., Gerstoft, J., Pedersen, B.K., Ullum, H.:
"Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1nfected patients."-i
Scand. J. Immunol., 2005, 61: 347-356.

Ostrowski, S.R., Piironen, T., Høyer-Hansen, G., Gerstoft, J., Pedersen, B.K. and Ullum, H.:
"High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1nfected patients."-i
J. Acquir. Immune Defic. Syndr., , 2005, 39: 23-31.

Danø, K., Behrendt, N.Høyer-Hansen, G., , Johnsen, M., Lund, L.R., Ploug, M. and Rømer, J.:
"Plasminogen activation and cancer."
Throm. Haemost., 2005, 93: 676-681.

Ostrowski, S.R., Ullum, H., Goka, B.Q., Høyer-Hansen, G., Obeng-Adjei, G., Pedersen, B.K., Akanmori, B.D. and Kurtzhals, J.A.:
"Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome."
J. Infect. Dis., 2005, 191: 1331-1341.

Ostrowski, S.R., Plomgaard,P., Fischer, C.P., Steensberg, A.S., Moller, K., Høyer-Hansen, G., Pedersen, B.K. and Ullum, H.:
"Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from periferal blood mononuclear cells."
Scand J Immunol., 2005, 61: 197-206.

Almasi, C.E., Høyer-Hansen, G., Christensen, I.J., Danø, K. and Pappot H.:
"Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue."
Lung Cancer, 2005; 48: 349-355.

Usher, P.A., Thomsen, O.F., Iversen, P., Johnsen, M., Brünner, N., Høyer-Hansen, G., Andreasen, P.A., Danø, K. and Nielsen, B.S.:
"Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue."
Int. J. Cancer, 2005; 113: 870-880.

Piironen, T., Laursen, B., Pass, J., List, K., Gårdsvoll, H., Ploug, M., Danø, K. and Høyer-Hansen, G.:
"Specific immunoassays for the detection of intact and cleaved forms of the urokinase receptor."
Clin. Chem., , 2004, 50: 2059-2068.

Illemann, M., Hansen, U., Nielsen, H.J., Andreasen, P.A., Høyer-Hansen, G., Lund, L.R., Danø, K. and Nielsen, B.S.:
"Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1."
Am J Clin Pathol., 2004, 122: 256-265.

Begum, F.D., Hogdall, C.K., Kjaer, S.K., Christensen, L., Blaakaer, J., Bock, J.E., Glud, E., Høyer-Hansen, G., Ring-Larsen, H. and Hogdall, E.V.:
"The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients."
Anticancer Res. 2004;24:1981-5.

Nordengren, J., Pilka, R., Noskova, V., Ehinger, A., Domanski, H., Andersson, C., Høyer-Hansen, G., Hansson, S.R. and Casslen, B.:
"Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle."
Mol Hum Reprod., 2004, 10: 655-663.

Offersen, B.V., Nielsen, B.S., Høyer-Hansen, G., Rank, F., Hamilton-Dutoit, S., Overgaard, J. and Andreasen, P.A.:
"The myofibroblast is the predominant plasminogen activator inhibitor-1 expressing cell type in human breast carcinomas."
Am J Pathol., 2003, 163: 1887-1899.

Pass, J., Gårdsvoll, H., Lund, L.R., Danø, K. and Høyer-Hansen, G.: "Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knock-out mice: Membrane bound uPAR is not required for an antibody response."
Scand J Immunol., 2003, 58: 298-305.

Riisbro, R., Piironen, T., Brünner, N., Larsen, B., Nielsen, H.J., Stephens, R.W. and Høyer-Hansen, G.:
"Measurement of soluble urokinase plasminogen activator receptor in serum."
J. Clin. Ligand Assay, 2002, 25: 53-56.

Riisbro, R., Christensen, I.J., Piironen, T., Greenall, M., Larsen, B., Stephens, R.W., Han, C.Høyer-Hansen, G. , Smith, K., Brünner, N. and Harris, A.L.:
"Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer."
Clin. Cancer Res., 2002, 8: 1132-1141.

Høyer-Hansen, G., , Pessara, U., Holm,A., Pass, J., Weidle, U., Danø, K. and Behrendt, N.:
"Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor."
Biochem.J., , 2001, 358: 673-679.